Amgen Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 01/31/2023
Amgen Inc Stock Forecast and Price Target
Amgen Inc's most recent price target of $278.00 for 2023 was provided by renowned analysts over the past few months, with an average prediction of $278.00. If this prediction is correct, Amgen Inc's stock could rise by 2.31 percent from its current trading price. The potential increase for the stock is $278.00 per share, with a possible range of $180.00 to $325.00. If you are interested in AMGN stock, you should also look at its competitors.
2.31% Upside
Amgen Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last zero years, Amgen Inc's Price has fallen from $155.10 to $155.10 – a 0.00% decrease. In the next year, analysts expect Fair Value to reach $288.75 – an increase of 86.17%. For the next eight years, the forecast is for Fair Value to grow by 133.37%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$147.74 | $162.12 | 11.68% |
| NasdaqGS:ALXN Stock Forecast | Alexion Pharmaceuticals | - |
15
|
$182.50 | $177.38 | 29.40% |
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$115.35 | $115.45 | 4.03% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$85.14 | $88.18 | 1.01% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | $95.80 | 11.05% |
Amgen Inc Revenue Forecast for 2023 - 2025 - 2030
In the last zero years, Amgen Inc's Revenue has fallen from $25979.00T to $25979.00T – a 0.00% decrease. According to 24 prominent analysts, Amgen Inc's Revenue will fall by 100.00% in the next year, reaching $27.32B. By 2030, professionals believe that Amgen Inc's Revenue will decrease by 100.00%, reaching $28.05B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| EXEL Stock Forecast | Exelixis | Outperform |
16
|
$17.62 | $26.06 | 41.88% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$34.99 | $73.38 | 114.35% |
| CCXI Stock Forecast | ChemoCentryx | Outperform |
8
|
$51.99 | $34.75 | 24.06% |
Amgen Inc Dividend per Share Forecast for 2023 - 2025 - 2030
Amgen Inc's Dividend per Share has decreased In the last zero years, from $8.52 to $8.52 – a 0.00% drop. In the following year, 11 experts forecast Amgen Inc's Dividend per Share will decrease by 2.82%, to $8.28. Over the next eight years, experts anticipate that Amgen Inc's Dividend per Share will grow at a rate of 48.36%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.22 | $39.67 | 10.83% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$13.04 | $14.60 | 15.03% |
| BCRX Stock Forecast | BioCryst Pharmaceuticals | Outperform |
7
|
$10.55 | $17.08 | 23.22% |
Amgen Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last zero years, Amgen Inc's Free Cash Flow has gone down from $9031.00T to $9031.00T – a 0.00% drop. In the next year, 5 analysts estimate that Amgen Inc's Free Cash Flow will decrease by 100.00%, reaching $10.40B. According to professional forecasts, in 2030, Amgen Inc's Free Cash Flow will decrease by 100.00%, reaching $12.27B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$19.03 | $29.50 | 5.10% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$46.70 | $119.23 | 68.09% |
| SAGE Stock Forecast | Sage Therapeutics | Outperform |
6
|
$44.34 | $101.45 | 21.79% |
Amgen Inc Net Income Forecast for 2023 - 2025 - 2030
In the last zero years, Amgen Inc's Net Income has seen a drop from $5893.00T to $5893.00T – a 0.00% decrease. According to 22 major analysts, Amgen Inc's Net Income will fall by 100.00% in the next year, reaching $10.25B. Professionals believe that By 2030, Amgen Inc's Net Income will fall to $9.85B– a 100.00% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| IOVA Stock Forecast | Iovance Biotherapeutics | Outperform |
4
|
$7.95 | $34.92 | 239.62% |
| FATE Stock Forecast | Fate Therapeutics | Outperform |
7
|
$5.96 | $109.67 | 1275.84% |
| DVAX Stock Forecast | Dynavax Technologies | Buy |
11
|
$11.15 | $22.67 | 137.67% |
Amgen Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last zero years, Amgen Inc's EBITDA has fallen from $12801.00T to $12801.00T – a 0.00% decrease. According to 6 analysts, Amgen Inc's EBITDA will fall by 100.00% in the next year, reaching $16.28B. Professionals believe that By 2030, Amgen Inc's EBITDA will fall to $13.09B – a 100.00% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| XNCR Stock Forecast | Xencor | Buy |
6
|
$32.92 | $55.00 | 50.36% |
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$44.06 | $64.83 | 54.33% |
| TVTX Stock Forecast | Travere Therapeutics | Buy |
8
|
$22.38 | $41.00 | 87.67% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$29.48 | $53.75 | 32.29% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$27.44 | $44.60 | 82.22% |
| ENTA Stock Forecast | Enanta Pharmaceuticals | Outperform |
10
|
$53.36 | $90.20 | 25.56% |
Amgen Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last zero years, Amgen Inc's EPS has fallen from $10.34 to $10.34 – a 0.00% decrease. In the next year, analysts expect EPS to reach $19.25 – an increase of 86.17%. For the next eight years, the forecast is for EPS to grow by 133.37%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| RVNC Stock Forecast | Revance Therapeutics | Outperform |
6
|
$34.66 | $38.55 | -26.43% |
| MNKD Stock Forecast | MannKind | Outperform |
10
|
$5.47 | $6.50 | 0.55% |
| CERS Stock Forecast | Cerus | Buy |
6
|
$3.15 | $9.00 | 217.46% |